S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)

Sonnet BioTherapeutics (SONN) Competitors

$1.77
0.00 (0.00%)
(As of 02/23/2024 ET)

SONN vs. OBSV, BPTS, KPRX, JAN, IMNN, UPC, KZIA, GOVX, XCUR, and LSDI

Should you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include ObsEva (OBSV), Biophytis (BPTS), Kiora Pharmaceuticals (KPRX), JanOne (JAN), Imunon (IMNN), Universe Pharmaceuticals (UPC), Kazia Therapeutics (KZIA), GeoVax Labs (GOVX), Exicure (XCUR), and Lucy Scientific Discovery (LSDI). These companies are all part of the "pharmaceutical preparations" industry.

Sonnet BioTherapeutics vs.

Sonnet BioTherapeutics (NASDAQ:SONN) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation.

In the previous week, Sonnet BioTherapeutics had 2 more articles in the media than ObsEva. MarketBeat recorded 2 mentions for Sonnet BioTherapeutics and 0 mentions for ObsEva. ObsEva's average media sentiment score of 0.00 beat Sonnet BioTherapeutics' score of -0.53 indicating that ObsEva is being referred to more favorably in the news media.

Company Overall Sentiment
Sonnet BioTherapeutics Negative
ObsEva Neutral

36.8% of Sonnet BioTherapeutics shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 2.0% of Sonnet BioTherapeutics shares are held by insiders. Comparatively, 14.4% of ObsEva shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Sonnet BioTherapeutics currently has a consensus price target of $88.70, suggesting a potential upside of 4,996.53%. Given Sonnet BioTherapeutics' higher possible upside, research analysts clearly believe Sonnet BioTherapeutics is more favorable than ObsEva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sonnet BioTherapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
ObsEva
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

ObsEva received 302 more outperform votes than Sonnet BioTherapeutics when rated by MarketBeat users. However, 80.95% of users gave Sonnet BioTherapeutics an outperform vote while only 54.53% of users gave ObsEva an outperform vote.

CompanyUnderperformOutperform
Sonnet BioTherapeuticsOutperform Votes
17
80.95%
Underperform Votes
4
19.05%
ObsEvaOutperform Votes
319
54.53%
Underperform Votes
266
45.47%

ObsEva has a net margin of 0.00% compared to Sonnet BioTherapeutics' net margin of -11,187.19%. ObsEva's return on equity of -416.36% beat Sonnet BioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sonnet BioTherapeutics-11,187.19% -519.54% -169.55%
ObsEva N/A -416.36%-92.01%

Sonnet BioTherapeutics has higher earnings, but lower revenue than ObsEva.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sonnet BioTherapeutics$150K34.18-$18.83MN/AN/A
ObsEva$20.11M0.31-$58.38M-$0.92-0.09

Sonnet BioTherapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Summary

ObsEva beats Sonnet BioTherapeutics on 8 of the 15 factors compared between the two stocks.


Get Sonnet BioTherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SONN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SONN vs. The Competition

MetricSonnet BioTherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$5.13M$6.69B$5.02B$7.52B
Dividend YieldN/A2.72%2.91%3.86%
P/E RatioN/A9.5994.6914.49
Price / Sales34.18142.303,101.9455.25
Price / CashN/A18.1887.6252.42
Price / Book1.994.564.344.62
Net Income-$18.83M$156.18M$112.46M$207.21M
7 Day Performance3.09%0.75%0.51%-1.26%
1 Month Performance24.16%10.15%6.49%3.04%
1 Year Performance-91.18%1.02%8.47%3.47%

Sonnet BioTherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OBSV
ObsEva
0 of 5 stars
$0.06
flat
N/A-54.4%$4.68M$20.11M-0.0748Gap Up
BPTS
Biophytis
1.8955 of 5 stars
$0.48
-2.0%
$15.00
+3,031.5%
-88.4%$4.67MN/A0.0026Positive News
Gap Down
KPRX
Kiora Pharmaceuticals
2.1737 of 5 stars
$0.64
-5.9%
$7.00
+993.8%
-90.0%$4.92MN/A0.0012Positive News
Gap Down
JAN
JanOne
0 of 5 stars
$1.00
+49.3%
N/A-43.5%$4.96M$39.61M0.00199Gap Down
High Trading Volume
IMNN
Imunon
1.1265 of 5 stars
$0.49
-2.0%
$12.00
+2,359.0%
-61.0%$4.59M$500,000.00-0.1531News Coverage
UPC
Universe Pharmaceuticals
0 of 5 stars
$1.39
+4.5%
N/A-57.0%$5.03M$32.31M0.00224
KZIA
Kazia Therapeutics
2.2376 of 5 stars
$0.28
+3.7%
$2.00
+621.0%
-67.1%$4.53M$20,000.000.002,021Upcoming Earnings
Gap Up
GOVX
GeoVax Labs
2.8261 of 5 stars
$2.54
-3.8%
$90.00
+3,443.3%
-81.1%$4.52M$80,000.00-0.1914News Coverage
Gap Up
XCUR
Exicure
2.758 of 5 stars
$0.59
-1.7%
N/A-48.9%$5.10M$28.83M0.357News Coverage
LSDI
Lucy Scientific Discovery
0 of 5 stars
$0.25
-3.9%
N/A-86.7%$4.33M$10,000.00-0.382Stock Split
News Coverage
Positive News

Related Companies and Tools

This page (NASDAQ:SONN) was last updated on 2/23/2024 by MarketBeat.com Staff